Compare PDC & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | SCLX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 27.9M |
| IPO Year | 2022 | 2020 |
| Metric | PDC | SCLX |
|---|---|---|
| Price | $2.53 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 65.6K | 36.7K |
| Earning Date | 09-18-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,253,000.00 |
| Revenue This Year | N/A | $118.16 |
| Revenue Next Year | N/A | $186.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $1.81 |
| 52 Week High | $8.40 | $27.00 |
| Indicator | PDC | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 12.99 |
| Support Level | N/A | N/A |
| Resistance Level | $3.82 | $7.77 |
| Average True Range (ATR) | 0.63 | 0.17 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 46.67 | 5.09 |
Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.